Despite our efforts at malaria control, malaria remains one of our most serious and deadly diseases. The failure of control stems in part from the parasite's intense transmission in many areas and from the emergence and spread of resistance of the malaria parasites and their mosquito vectors against most of the chemicals used to attack them. New methods for control are desperately needed. However, new methods will be useful only if they are effective (i.e., decrease transmission substantially) and evolutionarily sustainable (i.e., evolution-proof, in that they prevent evolution from eroding efficacy). We suggest microsporidian parasites that infect mosquitoes could be potentially effective and sustainable agents for malaria control. They may be effective because they target several epidemiologically important traits: survival of larvae (and thus number of adult mosquitoes), adult longevity, biting rate and the development of malaria within the mosquitoes. Even if each trait is affected only moderately, the intensity of transmission can be reduced considerably. They may be evolution-proof, for the evolutionarily most important trait is juvenile survival, whereas the two epidemiologically most important factors are traits of the adult mosquito: biting rate and longevity. Under the intense microsporidian pressure of a control programme, it is likely (if not inevitable) that the larvae evolve to survive microsporidian infection. However, if this larval tolerance to microsporidians is genetically correlated with the adult traits, tolerant mosquitoes may not live as long and bite less frequently than microsporidian-sensitive ones. While such a trade-off has not been measured, combining several studies suggests indirectly a negative genetic correlation between larval tolerance and adult longevity. Therefore, evolution might not undermine control; rather it might increase its effectiveness. While the evolution of resistance may be inevitable, the failure of control need not be.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/S0065-308X(08)00612-X | DOI Listing |
Sci Rep
January 2025
Institut de Recherche en Sciences de la Santé, IRSS, Bobo-Dioulasso, Burkina Faso.
Entomopathogenic fungi engineered to express insect-specific neurotoxins have demonstrated potential as microbial control agents against malaria mosquitoes. Currently, the primary application method is via direct contact of spores with indoor resting mosquitoes. However, many malaria-transmitting mosquitoes feed and rest outdoors.
View Article and Find Full Text PDFPLoS Med
January 2025
Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Background: Globally, over one-third of pulmonary tuberculosis (TB) disease diagnoses are made based on clinical criteria after a negative bacteriological test result. There is limited information on the factors that determine clinicians' decisions to initiate TB treatment when initial bacteriological test results are negative.
Methods And Findings: We performed a systematic review and individual patient data meta-analysis using studies conducted between January 2010 and December 2022 (PROSPERO: CRD42022287613).
Nat Commun
January 2025
Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, 06520, USA.
Plasmodium, the causative agents of malaria, are obtained by mosquitoes from an infected human. Following Plasmodium acquisition by Anopheles gambiae, mosquito gamma-interferon-inducible lysosomal thiol reductase (mosGILT) plays a critical role in its subsequent sporogony in the mosquito. A critical location for this development is the midgut, a tissue we show expresses mosGILT.
View Article and Find Full Text PDFBMC Health Serv Res
January 2025
Innovations & Grants, Stop TB Partnership, Global Health Campus - Chemin du Pommier 40, Le Grand-Saconnex, 1218, Geneva, Switzerland.
Introduction: In Pakistan, almost one-third of people who develop tuberculosis (TB) are missed by the National TB Program (NTP). A considerable number of people with TB receive treatment in the private sector but remain unnotified. This study documents the outcomes of an intervention to identify people with TB through private pharmacy engagement, building on mapping TB medicine sales in Punjab Province.
View Article and Find Full Text PDFCells
January 2025
Nuclear Signaling Laboratory, Monash Biomedicine Discovery Institute, Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia.
Signal-dependent transport into and out of the nucleus mediated by members of the importin (IMP) superfamily is crucial for eukaryotic function, with inhibitors targeting IMPα being of key interest as anti-infectious agents, including against the apicomplexan species and , causative agents of malaria and toxoplasmosis, respectively. We recently showed that the FDA-approved macrocyclic lactone ivermectin, as well as several other different small molecule inhibitors, can specifically bind to and inhibit and IMPα functions, as well as limit parasite growth. Here we focus on the FDA-approved antiparasitic moxidectin, a structural analogue of ivermectin, for its IMPα-targeting and anti-apicomplexan properties for the first time.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!